Safety, pharmacokinetics and pharmacodynamics of a novel γ-aminobutyric acid (GABA) receptor potentiator, HSK3486, in Chinese patients with hepatic impairment

References

• Wei Y, Qiu G, Lei B, et al. Oral delivery of propofol with methoxymethylphosphonic acid as the delivery vehicle. J Med Chem. 2017;60(20):8580–8590.
   PubMed Web of Science ®Google Scholar
• Bian Y, Zhang H, Ma S, et al. Mass balance, pharmacokinetics and pharmacodynamics of intravenous HSK3486, a novel anaesthetic, administered to healthy subjects. Br J Clin Pharmacol. 2021;87(1):93–105.
   PubMed Web of Science ®Google Scholar
• Qin L, Ren L, Wan S, et al. Design, synthesis, and evaluation of novel 2,6-Disubstituted phenol derivatives as general anesthetics. J Med Chem. 2017;60(9):3606–3617.
   PubMed Web of Science ®Google Scholar
• Li X, Yang D, Li Q, et al. Safety, pharmacokinetics, and pharmacodynamics of a single bolus of the γ-aminobutyric acid (GABA) receptor potentiator HSK3486 in healthy chinese elderly and non-elderly. Front Pharmacol. 2021;12:735700.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yu X, Zhu D, et al. Safety and efficacy of ciprofol vs propofol for sedation in intensive care unit patients with mechanical ventilation: a multi-center, open label, randomized, phase 2 trial. Chin Med J. 2022;135(9):1043–1051.
   PubMed Web of Science ®Google Scholar
• Luo Z, Tu H, Zhang X, et al. Efficacy and safety of HSK3486 for anesthesia/sedation in patients undergoing fiberoptic bronchoscopy: a multicenter, Double-Blind, Propofol-Controlled, randomized, phase 3 study. CNS Drugs. 2022;36(3):301–313.
   PubMed Web of Science ®Google Scholar
• Adam S, van Bommel J, Pelka M, et al. Propofol-induced injection pain: comparison of a modified propofol emulsion to standard propofol with premixed lidocaine. Anesth Analg. 2004;99(4):1076–1079.
   PubMed Web of Science ®Google Scholar
• Marik PE. Propofol: therapeutic indications and side-effects. Curr Pharm Des. 2004;10(29):3639–3649.
   PubMed Web of Science ®Google Scholar
• Adler AC. Propofol: Review of potential risks during administration. Aana J. 2017;85(2):104–107.
   PubMedGoogle Scholar
• Picard P, Tramèr MR. Prevention of pain on injection with propofol: a quantitative systematic review. Anesth Analg. 2000;90(4):963–969.
   PubMed Web of Science ®Google Scholar
• Sahinovic MM, Struys M, Absalom AR. Clinical pharmacokinetics and pharmacodynamics of propofol. Clin Pharmacokinet. 2018;57(12):1539–1558.
   PubMed Web of Science ®Google Scholar
• Liao J, Li M, Huang C, et al. Pharmacodynamics and pharmacokinetics of HSK3486, a novel 2,6-Disubstituted phenol derivative as a general anesthetic. Front Pharmacol. 2022;13:830791.
   PubMed Web of Science ®Google Scholar
• Pena MA, Horga JF, Zapater P. Variations of pharmacokinetics of drugs in patients with cirrhosis. Expert Rev Clin Pharmacol. 2016;9(3):441–458.
   PubMed Web of Science ®Google Scholar
• Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147–1161.
   PubMed Web of Science ®Google Scholar
• Rodighiero V. Effects of liver disease on pharmacokinetics. An update. Clin Pharmacokinet. 1999;37(5):399–431.
   PubMed Web of Science ®Google Scholar
• Periáñez-Párraga L, Martínez-López I, Ventayol-Bosch P, et al. Drug dosage recommendations in patients with chronic liver disease. Rev Esp Enferm Dig. 2012;104(4):165–184.
   PubMed Web of Science ®Google Scholar
• Delcò F, Tchambaz L, Schlienger R, et al. Dose adjustment in patients with liver disease. Drug Saf. 2005;28(6):529–545.
   PubMed Web of Science ®Google Scholar
• Chen X, Yan R, Bai Z, et al. Enhanced sedative efficacy and delayed recovery in propofol anesthesia in a rat model of hepatic cirrhosis. Int J Clin Exp Med. 2015;8(4):5723–5730.
   PubMed Web of Science ®Google Scholar
• Ou YC, Preston RA, Marbury TC, et al. A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment. Leuk Lymphoma. 2020;61(6):1355–1363.
   PubMed Web of Science ®Google Scholar
• Tsai HC, Lin YC, Ko CL, et al. Propofol versus midazolam for upper gastrointestinal endoscopy in cirrhotic patients: a Meta-analysis of randomized controlled trials. PLoS One. 2015;10(2):e0117585.
   PubMed Web of Science ®Google Scholar
• Suh SJ, Yim HJ, Yoon EL, et al. Is propofol safe when administered to cirrhotic patients during sedative endoscopy? Korean J Intern Med. 2014;29(1):57–65.
   PubMed Web of Science ®Google Scholar
• Starczewska MH, Mon W, Shirley P. Anaesthesia in patients with liver disease. Curr Opin Anaesthesiol. 2017;30(3):392–398.
   PubMed Web of Science ®Google Scholar
• Costela JL, Jiḿenez R, Calvo R, et al. Serum protein binding of propofol in patients with renal failure or hepatic cirrhosis. Acta Anaesthesiol Scand. 1996;40(6):741–745.
   PubMed Web of Science ®Google Scholar
• Servin F, Cockshott ID, Farinotti R, et al. Pharmacokinetics of propofol infusions in patients with cirrhosis. Br J Anaesth. 1990;65(2):177–183.
   PubMed Web of Science ®Google Scholar
• Servin F, Desmonts JM, Farinotti R, et al. Pharmacokinetics of propofol administered by continuous infusion in patients with cirrhosis. Preliminary results. Anaesthesia. 1988;43 Suppl(Suppl):23–24.
   PubMedGoogle Scholar
• Servin F, Desmonts JM, Haberer JP, et al. Pharmacokinetics and protein binding of propofol in patients with cirrhosis. Anesthesiology. 1988;69(6):887–891.
   PubMed Web of Science ®Google Scholar